Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients (clinicaltrials.gov) - Mar 25, 2020 - P1; N=15; Recruiting; Sponsor: United BioPharma; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2019 ➔ Dec 2021
Clinical • Trial completion date • Trial primary completion date
|